Torigen Pharmaceuticals, Inc. produces an experimental Autologous Prescription Product regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.

Torigen Pharmaceuticals, Inc. produces an experimental Autologous Prescription Product regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.

Torigen Pharmaceuticals, Inc. produces an experimental Autologous Prescription Product regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.

Current Clinical Studies

Current Clinical Studies

Current Clinical Studies

Equine Squamous Cell Carcinoma

Equine Squamous Cell Carcinoma

Equine Squamous

Cell Carcinoma

This study is a fully funded clinical study for horses with non-ocular (away from the eye) squamous cell carcinoma. The study will be conducted through multiple study sites across the United States. Horses must be within the geographic areas of Southwest Texas, Southwest Upstate New York, Arizona, North Central North Carolina/South Central Virginia, Central California, and Northwest Florida to participate. The study length is 6 months.

This study is a fully funded clinical study for horses with non-ocular (away from the eye) squamous cell carcinoma. The study will be conducted through multiple study sites across the United States. Horses must be within the geographic areas of Southwest Texas, Southwest Upstate New York, Arizona, North Central North Carolina/South Central Virginia, Central California, and Northwest Florida to participate. The study length is 6 months.

Eligibility criteria:

  • Horses ≥ 12 months of age

  • Horses with a suspicion of non-ocular Squamous Cell Carcinoma (Diagnosis will be confirmed prior to study treatment)

  • Horses with chronic disease that is well controlled and life expectancy >6 months

  • Horse owner must be willing to comply with all scheduled study visits


Exclusion criteria:

  • Concurrent diagnosis of malignant cancer other than squamous cell carcinoma with an expected survival <6 months

  • Previous treatment with radiation therapy or immunotherapy

  • Pregnant or lactating

Other inclusion/exclusion criteria not listed will be discussed with you, including medications that are not allowed.


Study details:

Your horse will be screened to confirm that they can be included in the study. During screening the study site will obtain a medical history, physical examination, measurements and photos of your horse’s mass(es), blood and urine, and tissue samples from the mass(es). These procedures may be repeated throughout the study. This is an open label, non-randomized, prospective clinical trial and all horses will receive the study treatment.


Owner benefit:

This is a fully funded clinical trial. All study tests, study procedures, and study treatment is no cost to you. If your horse has a reaction to the study treatment, the Sponsor will cover the costs relating to the study treatment up to $750. Any costs above $750, the Sponsor will work with the study veterinarian to cover reasonable expenses relating to side effects from the study treatment. If your horse is excluded or removed from the study, you can pursue further care for your horse with no penalty (future examinations and procedures will not be covered by the study).

Study contact information:

If you are interested in the study and your horse is in one of the geographic areas listed above, please reach out to horsestudy@knoell.com

6 Executive Dr., Suite 118

Farmington, CT 06032

P: 860.519.9956

6 Executive Dr., Suite 118

Farmington, CT 06032

P: 860.519.9956

©2024 Torigen Pharmaceuticals Inc. | All rights reserved

©2024 Torigen Pharmaceuticals Inc. | All rights reserved